↓ Skip to main content

Regulatory Dendritic Cells for Immunotherapy in Immunologic Diseases

Overview of attention for article published in Frontiers in immunology, January 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter
5 X users
patent
2 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
149 Dimensions

Readers on

mendeley
191 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Regulatory Dendritic Cells for Immunotherapy in Immunologic Diseases
Published in
Frontiers in immunology, January 2014
DOI 10.3389/fimmu.2014.00007
Pubmed ID
Authors

John R. Gordon, Yanna Ma, Laura Churchman, Sara A. Gordon, Wojciech Dawicki

Abstract

We recognize well the abilities of dendritic cells to activate effector T cell (Teff cell) responses to an array of antigens and think of these cells in this context as pre-eminent antigen-presenting cells, but dendritic cells are also critical to the induction of immunologic tolerance. Herein, we review our knowledge on the different kinds of tolerogenic or regulatory dendritic cells that are present or can be induced in experimental settings and humans, how they operate, and the diseases in which they are effective, from allergic to autoimmune diseases and transplant tolerance. The primary conclusions that arise from these cumulative studies clearly indicate that the agent(s) used to induce the tolerogenic phenotype and the status of the dendritic cell at the time of induction influence not only the phenotype of the dendritic cell, but also that of the regulatory T cell responses that they in turn mobilize. For example, while many, if not most, types of induced regulatory dendritic cells lead CD4(+) naïve or Teff cells to adopt a CD25(+)Foxp3(+) Treg phenotype, exposure of Langerhans cells or dermal dendritic cells to vitamin D leads in one case to the downstream induction of CD25(+)Foxp3(+) regulatory T cell responses, while in the other to Foxp3(-) type 1 regulatory T cells (Tr1) responses. Similarly, exposure of human immature versus semi-mature dendritic cells to IL-10 leads to distinct regulatory T cell outcomes. Thus, it should be possible to shape our dendritic cell immunotherapy approaches for selective induction of different types of T cell tolerance or to simultaneously induce multiple types of regulatory T cell responses. This may prove to be an important option as we target diseases in different anatomic compartments or with divergent pathologies in the clinic. Finally, we provide an overview of the use and potential use of these cells clinically, highlighting their potential as tools in an array of settings.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 191 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Chile 1 <1%
Ireland 1 <1%
Brazil 1 <1%
United States 1 <1%
Poland 1 <1%
Unknown 186 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 40 21%
Researcher 37 19%
Student > Master 26 14%
Student > Bachelor 22 12%
Student > Doctoral Student 9 5%
Other 22 12%
Unknown 35 18%
Readers by discipline Count As %
Agricultural and Biological Sciences 50 26%
Immunology and Microbiology 44 23%
Medicine and Dentistry 22 12%
Biochemistry, Genetics and Molecular Biology 18 9%
Pharmacology, Toxicology and Pharmaceutical Science 4 2%
Other 12 6%
Unknown 41 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2021.
All research outputs
#4,191,860
of 25,373,627 outputs
Outputs from Frontiers in immunology
#4,511
of 31,516 outputs
Outputs of similar age
#46,317
of 319,280 outputs
Outputs of similar age from Frontiers in immunology
#9
of 97 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 31,516 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,280 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.